| Authors: |
Schavgoulidze A; Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse, France., Cui J; 1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA, United States., Encinas J; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., United States., Favasuli VK; Candiolo Cancer Institute, FPO-IRCCS, Candiolo (TO), Italy., Talluri S; DFCI, Boston, Massachusetts, United States., Mahéo S; IUCT, TOULOUSE, France., Cerutti C; Institut Universitaire du Cancer de Toulouse-Oncopole, 31100, France., Shammas MA; Dana Farber Cancer Institute, Boston, Massachusetts, United States., Primo D; Vivia Biotech, Madrid, Spain., Vicente C; University of Navarra, Pamplona, Spain., Larrayoz M; CIMA, Pamplona, Spain., Martínez-Climent JA; Center for Applied Medical Research (CIMA), University of Navarra, Pamplona, Spain., Anderson KC; Dana-Farber Cancer Institute, Boston, Massachusetts, United States., Aktas Samur A; Dana Farber Cancer Institution, Boston, Massachusetts, United States., Samur MK; Dana-Farber Cancer Institute and Harvard School of Public Health, Boston, Massachusetts, United States., Avet-Loiseau H; University Hospital, Sarzeau, France., Corre J; Unité de Genomique du Myélome, IUC- T Oncopole, TOULOUSE, France., Munshi NC; Dana Farber Cancer Institute, Boston, Massachusetts, United States., Fulciniti M; Dana Farber Cancer Institute, Boston, Massachusetts, United States. |
